CoChat

Glucagon Receptor Antagonism Improves Glucose Metabolism and Cardiac Function by Promoting AMP-Mediated Protein Kinase in Diabetic Mice

Open access
Sharma, Ankit X., Quittner-Strom, Ezekiel B., Lee, Young, Johnson, Joshua A., Martin, Sarah A., Yu, Xinxin, Li, Jianping, Lu, John, Cai, Zheqing, Chen, Shiuhwei, Wang, May-yun, Zhang, Yiyi, Pearson, Mackenzie J., Dorn, Andie C., McDonald, Jeffrey G., Gordillo, Ruth, Yan, Hai, Thai, Dung, Wang, Zhao V., Unger, Roger H., Holland, William L. · 2018 · Cell Reports
Cited by 71

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

The antidiabetic potential of glucagon receptor antagonism presents an opportunity for use in an insulin-centric clinical environment. To investigate the metabolic effects of glucagon receptor antagonism in type 2 diabetes, we treated Lepr db/db and Lep ob/ob mice with REMD 2.59, a human monoclonal antibody and competitive antagonist of the glucagon receptor. As expected, REMD 2.59 suppresses hepatic glucose production and improves glycemia. Surprisingly, it also enhances insulin action in both liver and skeletal muscle, coinciding with an increase in AMP-activated protein kinase (AMPK)-mediated lipid oxidation. Furthermore, weekly REMD 2.59 treatment over a period of months protects against diabetic cardiomyopathy. These functional improvements are not derived simply from correcting the systemic milieu; nondiabetic mice with cardiac-specific overexpression of lipoprotein lipase also show improvements in contractile function after REMD 2.59 treatment. These observations suggest that hyperglucagonemia enables lipotoxic conditions, allowing the development of insulin resistance and cardiac dysfunction during disease progression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.celrep.2018.01.065

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 71

Metadata

Authors
Sharma, A. X., Quittner-Strom, E. B., Lee, Y., Johnson, J. A., Martin, S. A., Yu, X., Li, J., Lu, J., Cai, Z., Chen, S., Wang, M.-Y., Zhang, Y., Pearson, M. J., Dorn, A. C., McDonald, J. G., Gordillo, R., Yan, H., Thai, D., Wang, Z. V., Unger, R. H., & Holland, W. L.
Venue
Cell Reports
Publisher
Elsevier BV
Published
2018-02
Volume
22
Issue
7
Pages
1760-1773
ISSN
2211-1247 (ISSN-L)
OpenAlex
W2787153479
Cited by
71
References
16
FWCI
5.29
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glucagon Receptor Antagonism Improves Glucose Metabolism and Cardiac Function by Promoting AMP-Mediated Protein Kinase in Diabetic Mice. https://app.cochat.ai/papers/10.1016/j.celrep.2018.01.065
The paper
Sharma, A. X., Quittner-Strom, E. B., Lee, Y., Johnson, J. A., Martin, S. A., Yu, X., Li, J., Lu, J., Cai, Z., Chen, S., Wang, M.-Y., Zhang, Y., Pearson, M. J., Dorn, A. C., McDonald, J. G., Gordillo, R., Yan, H., Thai, D., Wang, Z. V., . . . Holland, W. L. (2018). Glucagon Receptor Antagonism Improves Glucose Metabolism and Cardiac Function by Promoting AMP-Mediated Protein Kinase in Diabetic Mice. Cell Reports. https://doi.org/10.1016/j.celrep.2018.01.065

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.